Dr Nicholas Spencer Appointed Vice Convenor of Clinical Advisory Group

16 October 2025

AXREM Appoints Dr Nicholas Spencer as Vice Convenor of Clinical Advisory Group

AXREM is delighted to announce the appointment of Dr Nicholas Spencer as Vice Convenor of the AXREM Clinical Advisory Group (CAG), further strengthening our commitment to clinical excellence, collaboration, and sector-wide impact.

Dr Spencer is a specialist radiologist with extensive experience as a clinical leader within the NHS and executive roles in UK independent sector healthcare delivery. His passion for improving patient pathways and outcomes is matched by his dedication to fostering collaborative, high-performing clinical teams.

Since joining AGFA as Chief Clinical Information Officer in early 2022, Dr Spencer has continued to expand his industry network, building on the foundations laid during his tenure as a UKIO working party member from 2015 to 2024. He is an active contributor to AXREM’s Digital Pathology and AI/Imaging IT Special Focus Groups, bringing deep insight and energy to their wide-ranging collaborative work.

Commenting on his appointment, Dr Spencer said: “It is a privilege to be offered this role, and I hope to use my network and experiences across UK healthcare to promote the work of AXREM, ensuring partnerships strive to continue to improve patient care and outcomes.”

The AXREM Clinical Advisory Group was established to provide expert clinical advice, input, and validation to the AXREM Executive and its Special Focus Groups. The CAG plays a vital role in shaping publications, policy development, external communications, and industry engagement. It ensures that all AXREM outputs are clinically accurate, relevant, and aligned with current best practice.

Kaye Bonython, Convenor of the Clinical Advisory Group said upon the appointment “I am delighted that Dr Nicolas Spencer has accepted the role as Vice Convenor of the Clinical Advisory Group. His wealth of experience across the clinical, academic and industry fields will be an invaluable asset to the group and will ensure AXREM will continue to reach the highest level of excellence”.

The group also serves as a consultative body, offering high-level clinical guidance to external organisations and partners as directed by the AXREM CEO. With Dr Spencer’s leadership and vision, the CAG is poised to further elevate AXREM’s influence and impact across the healthcare landscape.

AXREM CEO, Sally Edgington said: “We are thrilled to welcome Dr Spencer into this leadership role. His clinical expertise, strategic insight, and commitment to collaborative improvement make him an ideal Vice Convenor. We look forward to the continued growth and influence of the Clinical Advisory Group under Kaye Bonython and Nicks stewardship.”

For more information about AXREM click here and the Clinical Advisory Group, click here.